Hans Prenen

Antwerp University Hospital

Research Interests

Explore related searches

Contact this professor

Google Scholar

Articles (20)

Collaborators (8)

Guy Van Camp

University of Antwerp

Matthew Krebs

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

Martin Forster

University College London

UNITED KINGDOM

Christof Vulsteke

University of Antwerp

Marc Peeters

University of Antwerp

Saleh Alessy

King's College London

UNITED KINGDOM

Ruth Plummer

Clinical Professor

Newcastle University

UNITED KINGDOM

James Spicer

King’s College London

UNITED KINGDOM

Hans Prenen

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (8)

Guy Van Camp

Matthew Krebs

Martin Forster

Christof Vulsteke

Marc Peeters

Saleh Alessy

Ruth Plummer

James Spicer

How do I reach out?

Meet Kite AI

Hans Prenen

Research Interests

Explore related searches

Contact this professor

Articles (20)

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours

A phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

A plain language summary of POLARIS

AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted Cancers

Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors

Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients.

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma

Intersectionality Between Country, Gender and Funding in Authorship for Phase III Trials Presented at the ASCO Annual Meeting 2022

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital

The Role of Immunotherapy in Esophageal and Gastric Cancer

Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study

A Belgian Population-Based Study Reveals Subgroups of Right-Sided Colorectal Cancer with a Better Prognosis Compared to Left-sided Cancer

Breast tumors interfere with endothelial TRAIL at the premetastatic niche to promote cancer cell seeding

Immediate hypersensitivity reactions to antineoplastic agents

Cellular senescence in cancer: clinical detection and prognostic implications

Excellent response to MEK inhibition in an AGK-BRAF gene fusion driven carcinoma

Collaborators (8)

Guy Van Camp

Matthew Krebs

Martin Forster

Christof Vulsteke

Marc Peeters

Saleh Alessy

Ruth Plummer

James Spicer

How do I reach out?

Meet Kite AI